# Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

Study · id `cardio:ct-nct03994471` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03994471](<https://clinicaltrials.gov/study/NCT03994471>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03994471

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 170 participants.

## Technical summary

Registry record NCT03994471. Randomized; single masking; primary purpose treatment. Start 2022-12-14 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 170 participants (planned count; ClinicalTrials.gov record NCT03994471, source copy `cardio:ctgov-nct03994471-2026-03-24`, retrieved 2026-10-26)
- Started: 2022-12-14 (actual) (ClinicalTrials.gov record NCT03994471, source copy `cardio:ctgov-nct03994471-2026-03-24`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT03994471, source copy `cardio:ctgov-nct03994471-2026-03-24`, retrieved 2026-10-26)
- Completion: 2027-04-28 (anticipated) (ClinicalTrials.gov record NCT03994471, source copy `cardio:ctgov-nct03994471-2026-03-24`, retrieved 2026-10-26)
- Countries: Denmark; Germany; Italy; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT03994471, source copy `cardio:ctgov-nct03994471-2026-03-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03994471-2026-03-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
- Acronym: ELIXIR
- Condition: End Stage Renal Disease
- Intervention (Drug): XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght
- Intervention (Drug): 1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution
- Lead sponsor: Iperboreal Pharma Srl
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: 060de8b1f6c976c28d86700c5c163c3ad958a3a6ff48829d0f03aea8b8937e4a
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
